PMO Interview with the Innovator Series: Volume 4
Thomas C. Reynolds, MD, PhD
Video Categories: PMO Interview with the Innovator Series
Dr. Sanjiv Agarwala analyzes anti-PD-1 and anti-PD-L1 therapies in terms what they do and their unique toxicities and response patterns.
PMO is pleased to offer the department “The Biomarker” to discuss the identification of biomarkers in patients with cancer and the prognostic/predictive impact and clinical decision-making implications of that marker. This month, we focus on KIT mutations in melanoma patients. Dr Sanjiv Agarwala provides his insights on this provocative topic.